Julie Cassecuel

Nantes, 44000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients.

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients.

Journal: Annales de dermatologie et de venereologie

Published: December 22, 2024

Real-world outcomes of adjuvant therapies in stage III/IV melanoma: Insights from the French RIC-MEL cohort.

Real-world outcomes of adjuvant therapies in stage III/IV melanoma: Insights from the French RIC-MEL cohort.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 05, 2024

Evolution of the sentinel lymph node procedure following the approval of adjuvant anti-PD-1 therapy for stage IIB and IIC melanoma: A multicenter study from RICMEL database.

Evolution of the sentinel lymph node procedure following the approval of adjuvant anti-PD-1 therapy for stage IIB and IIC melanoma: A multicenter study from RICMEL database.

Journal: Annales de dermatologie et de venereologie

Published: September 27, 2024

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas.

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 11, 2024

NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial.

NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 03, 2024

Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.

Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 29, 2022

Impact of adjuvant radiation therapy on survival and recurrence in patients with stage I-III Merkel cell carcinoma: A retrospective study of 312 patients.

Impact of adjuvant radiation therapy on survival and recurrence in patients with stage I-III Merkel cell carcinoma: A retrospective study of 312 patients.

Journal: Journal of the American Academy of Dermatology

Published: March 03, 2022

TOXICAN: a guide for grading dermatological adverse events of cancer treatments.

TOXICAN: a guide for grading dermatological adverse events of cancer treatments.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: June 20, 2017

Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.

Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.

Journal: International journal of dermatology

Published: May 19, 2016

Showing 1-9 of 9

Last Updated: 09/26/2026